Linda Raeder, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 27159 Oriole Rd, Princess Anne, MD 21853 Phone: 410-651-2879 |
News Archive
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
During the pandemic, it has become increasingly evident that people with cardiovascular disease and obesity are at a much higher risk of developing very severe, even fatal COVID-19 disease.
Borrowing from several statistical science models, an interdisciplinary team of researchers from the University of Illinois at Urbana-Champaign has developed a novel computational approach for massively accelerating the search for a hepatitis C vaccine.
A team of Massachusetts General Hospital investigators has developed a device with the potential of shortening the time required to rapidly diagnose pathogens responsible for health-care-associated infections from a couple of days to a matter of hours.
› Verified 3 days ago